Indication
Chronic Graft-versus-host disease
14 clinical trials
12 products
3 drugs
Clinical trial
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic TherapyStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Product
INCA034176Clinical trial
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)Status: Terminated, Estimated PCD: 2023-12-11
Product
BelumosudilClinical trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseStatus: Not yet recruiting, Estimated PCD: 2027-03-05
Product
RuxolitinibProduct
CorticosteroidsProduct
AxatilimabClinical trial
A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic TherapyStatus: Active (not recruiting), Estimated PCD: 2023-06-29
Clinical trial
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213Status: Active (not recruiting), Estimated PCD: 2024-07-10
Product
SCM-CGHClinical trial
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Activity, and Efficacy of SNDX- 6352 in Subjects With Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Prior TherapyStatus: Active (not recruiting), Estimated PCD: 2022-08-12
Product
SNDX-6352Clinical trial
Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative DiseasesStatus: Completed, Estimated PCD: 2023-01-06
Product
DexamethasoneClinical trial
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell TransplantStatus: Terminated, Estimated PCD: 2021-09-20
Product
IbrutinibDrug
VarlilumabClinical trial
Pharmacokinetics and Pharmacodynamic Study of Ruxolitinib for the Management of Acute and Chronic Graft Versus Host DiseaseStatus: Completed, Estimated PCD: 2023-05-13
Clinical trial
A Pilot Study of INCB039110 (Itacitinib) for the Treatment of Steroid Refractory Chronic Graft-Versus-Host DiseaseStatus: Terminated, Estimated PCD: 2023-09-07
Product
ItacitinibClinical trial
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-DiseaseStatus: Active (not recruiting), Estimated PCD: 2017-08-01
Drug
IL-2Clinical trial
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
AcalabrutinibClinical trial
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)Status: Recruiting, Estimated PCD: 2024-10-13
Drug
cyclophosphamideProduct
Anti-Thymocyte globulin